Stockscreener 앱 받기
4.10
1.74%
0.07
전일 마감가:
$4.03
열려 있는:
$4.1
하루 거래량:
223.94K
Relative Volume:
1.74
시가총액:
$728.82M
수익:
$842.96M
순이익/손실:
$-185.63M
주가수익비율:
-7.7962
EPS:
-0.5259
순현금흐름:
$-228.52M
1주 성능:
+3.54%
1개월 성능:
-4.43%
6개월 성능:
-10.48%
1년 성능:
-16.16%
1일 변동 폭
$4.08
$4.1499
1주일 범위
$3.78
$4.1499
52주 변동 폭
$2.84
$5.6405
Evotec Se Adr Stock (EVO) Company Profile
EVO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
4.10 | 1.41B | 842.96M | -185.63M | -228.52M | -0.5259 |
|
HLN
Haleon Plc Adr
|
10.93 | 50.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
168.59 | 73.64B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.92 | 4.12M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 45.57B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.52 | 20.82B | 16.54B | -1.64B | 749.00M | -1.45 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-24 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-10-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-08-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-07-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-07-11 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-04-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-06-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-04-04 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | 개시 | H.C. Wainwright | Buy |
| 2022-11-16 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-08-10 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | 재개 | Cowen | Outperform |
| 2022-01-07 | 재개 | Citigroup | Neutral |
모두보기
Evotec Se Adr 주식(EVO)의 최신 뉴스
8 New 4-Star Stocks - Morningstar
Evotec SE ADR (EVO) Strikes $4.73: The Risk Seems Worthwhile At This Price - Stocksregister
Evotec SE (EVO) Stock Forecasts - Yahoo Finance
Evotec SE ADR earnings missed by $0.03, revenue fell short of estimates - Investing.com Nigeria
Evotec Ag Earnings Call: Mixed Sentiment Amid Growth - TipRanks
Evotec AG Reports Q1 2025 Earnings and Strategic Progress - TipRanks
Stock Information - Evotec
Evotec shares surge 51% following InvestingPro’s undervalued signal By Investing.com - Investing.com
Evotec SE ADR earnings beat by $0.08, revenue topped estimates - Investing.com Australia
Evotec SE Reports Strong Q4 2024 and New Strategy - TipRanks
Evotec Ag’s Earnings Call: Growth Amid Challenges - TipRanks
Evotec: Management Streamlines Strategy to Refocus on Core Strengths Amid Biologics Momentum - Morningstar
Antibody Discovery Market Size to Achieve USD 22,570 Mn by 2034 | Statifacts - GlobeNewswire Inc.
Evotec: Some Recovery Has Come, But Much More Is Expected - Seeking Alpha
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - MSN
Markets Brief: Are Bank Stocks Expensive? - Morningstar
Evotec SE withdraws acquisition offer - Investing.com India
Halozyme outlines plan to acquire Evotec for €2 billion By Investing.com - Investing.com UK
Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says - BNN Bloomberg
Halozyme proposes $2 billion acquisition of Evotec - Investing.com
Evotec Reports Strategic Growth Amidst Revenue Challenges - TipRanks
Evotec stock outlook clouded by strategy update delays, warns Jefferies - Investing.com
Annual General Meeting - Evotec
Investor Relations - Evotec
Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar
Evotec shares crash 36% on profit warning - Investing.com
Healthcare Sector - Morningstar
Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges - Investing.com
T. Rowe Price Raises Stake in Evotec SE - TipRanks
Evotec SE ADR earnings, Revenue miss in Q3 By Investing.com - Investing.com India
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J - Yahoo Finance
Together for Medicines That MatterEvotec - Evotec
Evotech and Roche subsidiary Genentech enter into drug discovery alliance - Proactive Investors USA
Evotec and Biogen Idec in research agreement - Proactive financial news
Evotec Se Adr (EVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
0.61%
자본화:
|
볼륨(24시간):